United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million.

Check Out Our Latest Analysis on United Therapeutics United Therapeutics Stock Down 1.6 % UTHR stock opened at $313.60 on Wednesday. United Therapeutics has a 52-week low of $221.53 and a 52-week ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares.United Therapeutics’ Q4 earnings ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James ...

Jim Ratcliffe, co-owner, Manchester United, pictured with Ratcliffe’s proposed 100,000-seater Man United Stadium: MUFC cannot finance this from its own resources, and any banker or private equity boss ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm thinks the challenges to owning United in 2025 are ...

Manchester United fans have been urged by a supporters ... Debt is the road to ruin. “Matt Busby would be turning in his grave at the current plight of one of the world’s greatest football ...

CAMBRIDGE, United Kingdom, March 04, 2025 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease ...

Mark Hughes has praised Matt Dennis for his line-leading performances as he prepares to face his former club. The Carlisle United striker played an important role in Saturday’s vital 2-1 win ...